Neuropharmacology 2000-02-14

Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey.

M Bergström, K J Fasth, G Kilpatrick, P Ward, K M Cable, M D Wipperman, D R Sutherland, B Långström

文献索引:Neuropharmacology 39(4) , 664-70, (2000)

全文:HTML全文

摘要

Two high affinity and selective NK1-receptor antagonists, GR203040 and GR205171, were labelled with 11C and used in a series of experiments in rhesus monkeys. The purpose of these studies was to evaluate the brain uptake pattern and to explore the potential use of these compounds as PET ligands to characterise NK1-receptor binding. Seventeen studies were carried out with [11C]GR205171 and five experiments with [11C]GR203040, including baseline studies and studies performed after a 5 min infusion of cold compound at doses between 0.05 and 1 mg/kg. Both compounds demonstrated a significant and rapid uptake in the brain, but the uptake of [11C]GR205171 was more than double the uptake of [11C]GR203040. At tracer doses of [11C]GR205171 and all doses of [11C]GR203040 the uptake reached a plateau with no washout during the examination time, whereas [11C]GR205171 after pre-treatment with cold GR205171 showed a significant washout. Using a model with the cerebellum as reference, a method for quantitation was applied to the studies with [11C]GR205171 and the results indicated that the highest specific binding was in the striatum. The pre-treatment dose of cold GR205171 needed for 50% inhibition of binding was less than 0.04 mg/kg. The studies indicated that [11C]GR205171 could be used for the in vivo characterisation of NK1-receptor binding.


相关化合物

  • GR 203040

相关文献:

Attenuation of the gerbil writhing response by mu-, kappa- and delta-opioids, and NK-1, -2 and -3 receptor antagonists.

2015-11-01

[Pharmacol. Biochem. Behav. 79(1) , 125-35, (2004)]

The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.

1995-12-01

[Br. J. Pharmacol. 116(8) , 3158-63, (1995)]

Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.

1995-12-22

[J. Med. Chem. 38(26) , 4985-92, (1995)]

The NK1 antagonist GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder.

1997-08-01

[Gen. Pharmacol. 29(2) , 245-50, (1997)]

GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity.

1996-08-27

[Regul. Pept. 65(1) , 45-53, (1996)]

更多文献...